TABLE 5.
Low/high monthly doses rates of the predominant phytocannabinoids and terpenoids consumed by patients of the study sample at one month intervals within a six-month period.
| T1 (N = 429) | T2 (N = 150) | T3 (N = 98) | T4 (N = 71) | T5 (N = 77) | T6 (N = 82) | Statistic (p) | |
|---|---|---|---|---|---|---|---|
| Number of patients (%) | |||||||
| Chemovar monthly dose (mg) - pPhytocannabinoids | |||||||
| ∆9-trans-tetrahydrocannabinol (THC) | |||||||
| Low (123–4,892) | 231 (54) | 81 (54) | 49 (50) | 28 (39) | 33 (43) | 35 (43) | 9.9 (0.07) |
| High (4,892–14,123) | 198 (46) | 69 (46) | 49 (50) | 43 (61) | 44 (57) | 47 (57) | |
| THC-4 C | |||||||
| Low (0.21–20) | 228 (53) | 80 (53) | 42 (43) | 27 (38) | 39 (51) | 38 (46) | 8.8 (0.11) |
| High (20–69) | 201 (47) | 70 (47) | 56 (57) | 44 (62) | 38 (49) | 44 (54) | |
| Tetrahydrocannabivarin (THCV) | |||||||
| Low (0.15–50) | 232 (54) | 76 (51) | 46 (47) | 28 (39) | 35 (45) | 37 (45) | 7.8 (0.17) |
| High (50–378) | 197 (46) | 74 (49) | 52 (53) | 43 (61) | 42 (55) | 45 (55) | |
| Cannabidiol (CBD) | |||||||
| Low (3–20) | 223 (52) | 81 (54) | 48 (49) | 29 (41) | 40 (52) | 33 (40) | 7.2 (0.20) |
| High (20–4,576) | 206 (48) | 69 (46) | 50 (51) | 42 (59) | 37 (48) | 49 (60) | |
| Cannabigerol (CBG) | |||||||
| Low (16–143) | 222 (52) | 81 (54) | 49 (50) | 27 (38) | 34 (44) | 41 (50) | 6.6 (0.25) |
| High (143–619) | 207 (48) | 69 (46) | 49 (50) | 44 (62) | 43 (56) | 41 (50) | |
| Cannabinol (CBN) | |||||||
| Low (0.21–19) | 223 (52) | 77 (51) | 48 (49) | 35 (49) | 38 (49) | 35 (43) | 2.5 (0.76) |
| High (19–106) | 206 (48) | 73 (49) | 50 (51) | 36 (51) | 39 (51) | 47 (57) | |
| Cannabichromene (CBC) | |||||||
| Low (10–55) | 223 (52) | 77 (51) | 52 (53) | 33 (46) | 37 (48) | 32 (39) | 5.5 (0.35) |
| High (55–356) | 206 (48) | 73 (49) | 46 (47) | 38 (54) | 40 (52) | 50 (61) | |
| 331–-18b | |||||||
| Low (4–29) | 216 (50) | 83 (55) | 53 (54) | 38 (54) | 36 (47) | 41 (50) | 2.2 (0.81) |
| High (29–157) | 213 (50) | 67 (45) | 45 (46) | 33 (46) | 41 (53) | 41 (50) | |
| 373–-15c | |||||||
| Low (0–20) | 233 (54) | 69 (46) | 45 (46) | 32 (45) | 40 (52) | 36 (44) | 6.8 (0.23) |
| High (20–113) | 196 (46) | 81 (54) | 53 (54) | 39 (55) | 37 (48) | 46 (56) | |
| Chemovar monthly dose (ppm)–Terpenoids# | |||||||
| α-Pinene | |||||||
| Low (3,211–23,413) | 149 (35) | 58 (39) | 29 (30) | 19 (27) | 19 (25) | 25 (30) | 12.0 (0.03) |
| High (23,413–471,725) | 125 (29) | 44 (29) | 33 (34) | 31 (44) | 33 (43) | 33 (40) | |
| β-Pinene | |||||||
| Low (2,630–17,807) | 145 (34) | 57 (38) | 25 (26) | 23 (32) | 25 (32) | 27 (33) | 5.2 (0.38) |
| High (17,807–132,146) | 129 (30) | 45 (30) | 37 (38) | 27 (38) | 37 (35) | 31 (38) | |
| Ledene | |||||||
| Low (1,071–31,064) | 147 (34) | 49 (33) | 29 (30) | 24 (34) | 29 (38) | 21 (26) | 7.0 (0.22) |
| High (31,064–104,502) | 127 (30) | 53 (35) | 33 (34) | 26 (37) | 23 (30) | 37 (45) | |
| Limonene | |||||||
| Low (1,948–55,720) | 145 (34) | 54 (36) | 26 (27) | 22 (31) | 27 (35) | 25 (30) | 4.8 (0.44) |
| High (55,720–414,243) | 129 (30) | 48 (32) | 36 (37) | 28 (39) | 25 (32) | 33 (40) | |
| Linalool | |||||||
| Low (1,951–66,760) | 137 (32) | 52 (35) | 29 (30) | 26 (37) | 29 (38) | 26 (32) | 1.6 (0.89) |
| High (66,760–464,197) | 137 (32) | 50 (33) | 33 (34) | 24 (34) | 23 (30) | 32 (39) | |
| Trans β-Farnesene | |||||||
| Low (921–25,305) | 143 (33) | 52 (35) | 36 (37) | 21 (30) | 24 (31) | 23 (28) | 6.2 (0.28) |
| High (25,305–84,717) | 131 (31) | 50 (33) | 26 (27) | 29 (41) | 28 (36) | 35 (43) | |
| α-Fenchol | |||||||
| Low (1,235–42,024) | 150 (35) | 51 (34) | 23 (23) | 21 (30) | 28 (36) | 26 (32) | 8.8 (0.12) |
| High (42,024–229,057) | 124 (29) | 51 (34) | 39 (40) | 29 (41) | 24 (31) | 32 (39) | |
| α-Humulene | |||||||
| Low (5,606–49,291) | 141 (33) | 52 (35) | 27 (28) | 23 (32) | 30 (39) | 27 (33) | 3.1 (0.68) |
| High (49,291–177,085) | 133 (31) | 50 (33) | 35 (36) | 27 (38) | 22 (29) | 31 (38) | |
| α-Terpineol | |||||||
| Low (1,342–37,067) | 146 (34) | 51 (34) | 27 (28) | 24 (34) | 30 (39) | 24 (29) | 5.1 (0.39) |
| High (37,067–129,191) | 128 (30) | 51 (34) | 35 (36) | 26 (37) | 22 (29) | 34 (41) | |
| β-Caryophyllene | |||||||
| Low (12,327–151,311) | 143 (33) | 53 (35) | 29 (30) | 24 (34) | 26 (34) | 24 (29) | 2.7 (0.74) |
| High (151,311–515,989) | 131 (31) | 49 (33) | 33 (34) | 26 (37) | 26 (34) | 34 (41) | |
| β-Myrcene | |||||||
| Low (4,260–75,339) | 142 (33) | 55 (37) | 29 (30) | 19 (27) | 25 (32) | 30 (37) | 4.2 (0.51) |
| High (75,339–577,044) | 132 (31) | 47 (31) | 33 (34) | 31 (44) | 27 (35) | 28 (34) | |
IQR, Inter quartile range; mg, mgilligrams; ppm, parts per million; T1-T6, one to six months follow ups, respectively; #, Terpenoid dose does not add up to 100% due to missing GC/MS/MS tests; all statistic tests were Pearson's Chi-squared.